Monitor for FDA feedback on clinical hold resolution—this is the primary catalyst. Cash runway extends into mid-2027 at current burn (excluding settlement). No near-term binary events; consider position sizing accordingly.
Price Chart
Executive Summary
Filana Therapeutics reported Q2 2026 results with a net loss of $8.6M ($0.18 per share), improving from $44.2M ($0.92) in Q2 2025 due to non-recurring litigation contingency. Cash burn remains controlled at $12.7M in first-half 2026, below prior guidance. The FDA clinical hold on the TSC epilepsy program persists, with no update on resolution timing. A $31.25M litigation settlement was paid into escrow, with unrestricted cash expected at $36-40M by year-end.
Key Financial Metrics
Key Facts
- Q2 2026 net loss $8.6M ($0.18/share) vs $44.2M ($0.92) in Q2 2025 — improvement driven by absence of $31.25M securities litigation contingency
- Cash and cash equivalents $82.7M at June 30, 2026, down from $95.5M at December 31, 2025
- Net cash used in operations first-half 2026 was $12.7M, below previous guidance
- Paid $31.25M litigation settlement into escrow on July 23, 2026 (cash restricted pending court approval)
- Company estimates unrestricted cash at year-end 2026 in range of $36-40M, implying $11-15M operating cash use in second half
- FDA clinical hold on simufilam proof-of-concept trial in TSC-related epilepsy continues; company engaging with FDA
- No product revenue; zero revenue reported
- Shares outstanding 48.3M as of July 27, 2026
Financial Impact
No revenue; net loss $8.6M for Q2 2026; cash burn $12.7M first-half 2026; litigation settlement $31.25M paid; year-end cash estimate $36-40M
Risk Factors
- FDA clinical hold may not be resolved, delaying or ending TSC epilepsy program
- Cash burn continues with no recurring revenue; further dilution possible if hold persists
- Litigation settlement (subject to court approval) consumes $31.25M of cash reserves
- Pre-revenue stage with no approved products and high execution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-004982 |
| Document: f8k_072826.htm | 0001171843-26-004982 |
| Document: 0001171843-26-004982-index-headers.html | 0001171843-26-004982 |
| Document: 0001171843-26-004982-index.html | 0001171843-26-004982 |
| Document: 0001171843-26-004982.txt | 0001171843-26-004982 |
| 8-K Data (Synthetic) | 0001171843-26-004982 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 8-K | $0.6885 | awaiting T+20 | — | $0.6483 (−5.84%) |
Sep 22, 2026 5w ago | 8-K | $1.03 $0.6900 | ▼ −33.01% | ▼ −32.45% | $0.6483 (−37.06%) |
Sep 18, 2026 5w ago | 8-K | $0.7395 $0.6820 | ▲ +7.78% | ▲ +6.87% | $0.6483 (+12.33%) |
Jul 29, 2026 12w ago | 8-K | $0.8696 $0.9244 | ▲ +6.30% | ▲ +1.28% | $0.6483 (−25.45%) |
Jun 15, 2026 19w ago | 8-K | $1.21 $1.15 | ▼ −4.96% | ▼ −4.21% | $0.6483 (−46.42%) |
May 7, 2026 24w ago | 8-K | $1.36 $1.36 | · 0.00% | ▲ +3.14% | $0.6483 (+52.33%) |
May 7, 2026 24w ago | Press Release | $1.36 $1.36 | · 0.00% | ▼ −3.14% | $0.6483 (−52.33%) |
Mar 12, 2026 32w ago | Press Release | $1.95 $1.64 | ▲ +15.90% | ▲ +17.87% | $0.6483 (+66.75%) |
Mar 10, 2026 33w ago | 8-K | $2.38 $1.70 | ▼ −28.57% | ▼ −28.42% | $0.6483 (−72.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers